CHICAGO - Tempus AI, Inc. (NASDAQ:TEM) announced results from its multimodal foundation models at the 2026 American Society of Clinical Oncology Annual Meeting today, according to a press release statement. The company’s shares jumped 11% over the past week, trading at $51.29 and valuing the AI-driven precision medicine firm at $9.2 billion.
The company’s transformer-based model was trained on 2.5 million longitudinal records, including more than 250 million pages of clinical notes, 450,000 digitized medical images, and 500,000 genomic and transcriptomic sequences. The model draws from Tempus’s database of more than 45 million de-identified patient journeys, with 1.5 million containing sequenced data.
In a zero-shot analysis of EGFR-mutant non-small cell lung cancer patients treated with osimertinib, the model demonstrated a C-index of 0.802 for overall survival with a p-value below 0.001. The model showed a hazard ratio of 4.536 between high- and low-risk patient subgroups.
The model produced prognostic value independent of molecular and clinical subgroups, stratifying overall survival of TP53-positive patients with a hazard ratio of 5.96 and progression-free survival in patients without CNS metastasis with a hazard ratio of 1.94.While Tempus continues to invest heavily in AI development, the company remains unprofitable with revenue of $1.36 billion over the last twelve months, though sales surged 70% year-over-year. According to InvestingPro analysis, the stock appears overvalued at current levels. Investors can access detailed valuation metrics and a comprehensive Pro Research Report on TEM, one of 1,400+ US equities covered with expert analysis.
Tempus reported the model assessed cohorts mirroring clinical trials KEYNOTE-189, FLAURA-2, and DESTINY in non-small cell lung cancer, outperforming standard Cox-PH modeling approaches in zero-shot settings.
"Foundation models, combined with agentic workflows, will help unlock the full potential of precision medicine," said Eric Lefkofsky, founder and CEO of Tempus.
The company stated its database contains more than 500 petabytes of data, including over 400,000 cancer records with genomic, transcriptomic, imaging, and clinical data. The model is designed to address prediction objectives anchored in overall survival and progression-free survival without requiring additional data or model fine-tuning.
In other recent news, Tempus AI, Inc. has received FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform. This approval allows Tempus to be the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. The test can now operate as a tumor-only assay when a matched normal specimen is unavailable. Additionally, Tempus announced an expansion of its Next platform to include six new cancer types, covering breast, colorectal, ovarian, prostate, and urothelial cancers. The company presented a study at the American Society of Clinical Oncology Annual Meeting, showcasing its AI-enabled clinical decision support system’s implementation across 662 early-stage non-small cell lung cancer patients. Furthermore, Tempus upgraded its Tempus Hub platform by integrating generative AI capabilities to assist healthcare providers in treating cancer patients. This upgrade connects AI capabilities with real-time patient data, offering access to test orders, results, treatment options, clinical trial information, and biomarker tracking. These developments highlight Tempus AI’s ongoing efforts to enhance its cancer treatment platforms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for TEM plus thousands of other stocks and find your next hidden gem with massive upside.